BCL2 and acute myeloid leukemia: To address this issue, we studied the influence of BCL2 bone marrow expression on patient outcome in a consecutive series of 176 AML patients at diagnosis (Dx), and when possible, at post-induction (PI, when the patient recovers blood count, between days 21–28 after induction [8]); morphological complete remission (CR) (i.e., <5% blasts in the bone marrow [8]) and at relapse (RL).